{{Rsnum
|rsid=1319501
|Gene=NAMPT
|Chromosome=7
|position=106285307
|Orientation=plus
|GMAF=0.1635
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=NAMPT
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 6.2 | 31.9 | 61.9
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 12.9 | 51.7 | 35.4
| ASW | 8.8 | 40.4 | 50.9
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 23.8 | 76.2
| LWK | 6.4 | 30.0 | 63.6
| MEX | 0.0 | 22.4 | 77.6
| MKK | 6.4 | 39.1 | 54.5
| TSI | 4.9 | 29.4 | 65.7
| HapMapRevision=28
}}{{PMID Auto
|PMID=19948877
|Title=Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels
}}

{{PMID Auto
|PMID=22251423
|Title=NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction
}}

{{PMID Auto
|PMID=17003359
|Title=Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population.
}}

{{PMID Auto
|PMID=20346149
|Title=Visfatin, glucose metabolism and vascular disease: a review of evidence.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}